Two in ADC partnership
Submitted by:
Andrew Warmington
Carbogen Amcis has formed a strategic partnership with pure-play biologics CDMO Celonics to offer fully integrated antibody-drug conjugate (ADC) development and manufacturing services. Both firms are Swiss. The offer will include:
- Cell line development and antibody production at scale
- Payload and linker synthesis and at-scale manufacturing
- ADC conjugation and sterile fill-finish
- Regulatory support and CMC documentation for IND, IMPD, and BLA filings
“This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors,” the two stated. “By combining their strengths, Celonic and Carbogen Amcis aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.”
Carbogen Amcis has been active in ADCs since 2005 and claims to be one of the earliest CDMOs to build dedicated ADC capabilities. It has dedicated conjugation suites in Switzerland and clinical‑to‑commercial and commercial manufacturing of sterile liquid drug‑product capability at a new greenfield facility in France.
Celonic, meanwhile, recently expanded its biologics development centre in Basel and its GMP manufacturing site in Heidelberg, adding a high-yield GS-CHOvolution cell line platform, enhanced perfusion-based technologies for process optimisation and commercial-scale biomanufacturing suites.